Who Paid My Doc
Marjorie Stock
Sleep Medicine Derry, NH Medical Doctor
NPI 1518914209 CMS profile 205194
14A Tsienneto Road, Suite 200, Derry, NH 03038
General payments
$243
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Marjorie Stock of Derry, NH is reported in the CMS Open Payments database as having received $243 across 13 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $22 | 1 | |
| 2022 | General | $59 | 3 | |
| 2020 | General | $66 | 4 | |
| 2019 | General | $95 | 5 |
Beside peers
- Marjorie Stock
- Sleep Medicine median
- Middle half of Sleep Medicine
- National median
In program year 2025, general payments to Marjorie Stock were reported at $0. Among 41 Sleep Medicine profiles paid that year, the median was $509 and the middle half received between $149 and $1,143.
Show as a table
| Year | Marjorie Stock | Sleep Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $95 | $276 | $99–$1,051 | $163 |
| 2020 | $66 | $154 | $53–$837 | $114 |
| 2021 | $0 | $311 | $144–$1,090 | $132 |
| 2022 | $59 | $312 | $80–$539 | $149 |
| 2023 | $22 | $439 | $154–$773 | $160 |
| 2024 | $0 | $450 | $149–$1,411 | $164 |
| 2025 | $0 | $509 | $149–$1,143 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
347
Drug cost
$6,370
Branded share of claims
11.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Azelastine Hcl | Generic | 66 | $1,622 | |
| Fluticasone Propionate | Generic | 71 | $1,179 | |
| Ipratropium Bromide | Generic | 33 | $1,119 | |
| Ofloxacin | Generic | 26 | $687 | |
| Cefuroxime Cefuroxime Axetil | Brand | 28 | $418 | |
| Fluocinolone Acetonide Oil | Generic | 11 | $402 | |
| Montelukast Sodium | Generic | 43 | $311 | |
| Doxycycline Hyclate | Generic | 27 | $246 | |
| Triamterene-Hydrochlorothiazid Triamterene/Hydrochlorothiazid | Brand | 13 | $206 | |
| Nystatin | Generic | 12 | $150 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 24 billing codesPaid by Medicare
$46,242
Medicare patients
359
Services billed
1,082
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 72% | |
| Arthritis | 47% | |
| Diabetes | 25% | |
| Ischemic heart disease | 19% | |
| Depression | 19% | |
| Osteoporosis | 18% | |
| Chronic kidney disease | 17% | |
| Heart failure | 14% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
13 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Sleep Medicine in New Hampshire
Practitioners in the same specialty and state, ranked by reported value.
All Sleep Medicine
Everyone recorded under this specialty, nationwide.
Doctors in New Hampshire
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.